Adults with metastatic castration-resistant prostate cancer invited to be in a research study

IRB/UVA Tracking #
22133
Principal Investigator
Robert Dreicer
Contact
Jennifer Drake
Contact Email
Contact Phone
434.297.7782
Official Trial Title
A PHASE 1, OPEN-LABEL STUDY IN TWO PARTS, EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF CCW702 IN PATIENTS WITH METASTATIC, CASTRATION RESISTANT PROSTATE ADENOCARCINOMA
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have metastatic castration-resistant prostate cancer (mCRPC). This is a phase I clinical trial and First-in-Human study, which means that this is the first time that a study patient will receive the study drug CCW702. The purpose of the study is to assess the safety, tolerability, the time course of the drug in your body known as pharmacokinetics, and the observed effects produced by the drug called pharmacodynamics of CCW702 (study drug) when given as an injection under your skin (subcutaneous injection) every other day for two weeks for a total of 6 doses in a twenty-eight (28) day cycle of dosing in patients like yourself who have been diagnosed with mCRPC.

The length of your participation is dependent on how you are responding to the study drug. If you and your physician decide that you are benefitting from the treatment, you can stay on the treatment until your cancer progresses, the dose is intolerable, or you decide to withdraw your consent to participate. The follow-up portion of the study will last up to 2 years.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04077021

Compensation

You will be reimbursed if you participate in this study. The parameters of the reimbursement will be communicated to you should you be interested in this study.